AVANIR Pharmaceuticals receives patent for low-dose quinidine formulations of Zenvia to treat PBA
Links shared publicly online about this topic.
- 1,392total visits
AVANIR Pharmaceuticals receives patent for low-dose quinidine formulations of Zenvia to treat PBA
AVANIR Pharmaceuticals, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new patent for its lead drug candidate Zenvia" (dextromethorphan/quinidine), extending the period of patent protection in the United States into late 2025. U.S. patent number 7,659,282 titled "Pharmaceutical Compositions Comprising Dextromethorphan and Quinidine for the Treatment of Neurological Disorders" was issued on February 9, 2010. The new patent will p
View full resource at news-medical.net
Most Recently Shared on February 10, 2010 at 2:27 pm By:
AVANIR Pharmaceuticals receives patent for low-dose quinidine formulations of Zenvia to treat PBA: AVANIR Pharmace... http://bit.ly/clEHcv
Advertisement
